Which pricing strategy is specifically encouraged by the Orphan Drug Act to stimulate development of medications for rare diseases?

The pharmaceutical industry employs various pricing strategies, particularly for rare disease treatments. The Orphan Drug Act of 1983 fundamentally changed how companies approach medication development for rare conditions. This pricing model has significant implications for healthcare systems, insurance providers, and patients. Test your knowledge about this specialized area of medical product pricing!

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Premium pricing with market exclusivity periods, allowing companies to recoup R&D costs from smaller patient populations
Penetration pricing with mandated price caps to ensure affordability for patients with rare conditions
Reference-based pricing where orphan drug costs must align with comparable non-orphan treatments
Value-based contracting requiring pharmaceutical companies to prove efficacy before full payment